National Cancer Center Announces Recipients of 2025-26 Research Fellowship Awards

Total of 11 awards totaling $676K will benefit researchers at Dana-Farber Cancer Institute, Weill Medical College of Cornell University, Massachusetts Institute of Technology, NYU Langone, Rockefeller University, Beckman Research Institute at City of Hope, and Columbia University

NEW YORK--(BUSINESS WIRE)--National Cancer Center is pleased to announce the recipients of its 2025-26 research grant awards and renewals, which support research fellows pursuing promising and innovative cancer research.

This year’s class includes a total of 11 recipients from diverse backgrounds and a broad universe of premier cancer research institutions. First-time recipients will receive $60,000 each and are eligible to receive an additional grant of $62,000 if he or she has demonstrated good progress at the conclusion of the first year.

“National Cancer Center’s mission identifies and funds promising projects by the best up-and-coming research fellows conducting research in the United States. We are excited by the high quality and promise of this year’s winning projects and remain grateful to all the supporters funding this important work,” said Victoria L. Seewaldt, M.D., City of Hope Comprehensive Cancer Center (Duarte, California), and Chair of NCC’s Scientific Advisory Board.

Recipients include: Shelby Roseman, Ph.D., Dana-Farber Cancer Institute; Kaiwan Sun, Ph.D., Dana-Farber Cancer Institute; Jiali Yu, Ph.D., Weill Medical College of Cornell University; Katharina Hoebel, M.D., Ph.D., Dana-Farber Cancer Institute; Jibin Sadasivan, Ph.D., Massachusetts Institute of Technology; Diego Martinez Alonso, Ph.D., Dana-Farber Cancer Institute; Nikita Jinna, Ph.D., Beckman Research Institute at City of Hope; Marija Simic, Ph.D., NYU Langone; Hengrui Liu, Ph.D., Rockefeller University; Suman Dash, Ph.D., Columbia University; and Yixin Hu, Ph.D., Rockefeller University.

Further details of these projects can be found on the NCC grants page here.

All award decisions are made by NCC’s Scientific Advisory Board. In addition to Dr. Seewaldt, the Scientific Advisory Board includes Jerome Ritz, M.D., Harvard Medical School; John M. Kirkwood, M.D., University of Pittsburgh Cancer Institute; Janet M.D. Plate, Ph.D.; and David Knorr, M.D., Ph.D., Translational Medicine Lead, Mariana Oncology. Darell D. Bigner, M.D., Ph.D., Duke University Medical Center, is Chair Emeritus.